Integer’s (ITGR) Buy Rating Reaffirmed at Northcoast Research

Northcoast Research reissued their buy rating on shares of Integer (NYSE:ITGR) in a report issued on Friday, Zacks.com reports. Northcoast Research also issued estimates for Integer’s Q3 2019 earnings at $1.07 EPS, Q4 2019 earnings at $1.14 EPS, FY2019 earnings at $4.43 EPS, Q2 2020 earnings at $1.35 EPS, Q3 2020 earnings at $1.28 EPS, Q4 2020 earnings at $1.29 EPS and FY2020 earnings at $4.97 EPS.

Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded Integer from a strong-buy rating to a hold rating in a research note on Wednesday, April 24th. Argus reduced their target price on Integer from $90.00 to $4.29 and set an average rating for the company in a research note on Wednesday, June 5th. They noted that the move was a valuation call. Finally, ValuEngine downgraded Integer from a hold rating to a sell rating in a research note on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $72.57.

NYSE:ITGR traded down $4.07 during trading hours on Friday, reaching $84.27. The company had a trading volume of 213,490 shares, compared to its average volume of 149,096. Integer has a 1-year low of $67.72 and a 1-year high of $92.61. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of 22.18 and a beta of 0.96. The stock has a 50 day moving average price of $82.93. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.49 and a current ratio of 2.55.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $1.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.17. The company had revenue of $314.20 million during the quarter, compared to the consensus estimate of $318.50 million. Integer had a return on equity of 13.37% and a net margin of 14.67%. Integer’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 earnings per share. On average, equities analysts anticipate that Integer will post 4.3 earnings per share for the current year.

In other Integer news, Director James F. Hinrichs bought 3,750 shares of Integer stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of $68.47 per share, with a total value of $256,762.50. Following the purchase, the director now directly owns 6,549 shares in the company, valued at approximately $448,410.03. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 2.24% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can raised its stake in Integer by 1.8% in the 1st quarter. Great West Life Assurance Co. Can now owns 39,913 shares of the medical equipment provider’s stock valued at $3,010,000 after purchasing an additional 692 shares during the last quarter. Rhumbline Advisers raised its stake in Integer by 1.5% in the 1st quarter. Rhumbline Advisers now owns 88,788 shares of the medical equipment provider’s stock valued at $6,696,000 after purchasing an additional 1,293 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in Integer in the 1st quarter valued at $45,000. Clark Capital Management Group Inc. acquired a new position in Integer in the 1st quarter valued at $2,812,000. Finally, O Shaughnessy Asset Management LLC raised its stake in Integer by 68.8% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 13,650 shares of the medical equipment provider’s stock valued at $1,024,000 after purchasing an additional 5,562 shares during the last quarter. 96.34% of the stock is owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.

Read More: Why are gap-down stocks important?

Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.